Pages that link to "Q39433857"
Jump to navigation
Jump to search
The following pages link to Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma (Q39433857):
Displaying 50 items.
- Cancer genome landscapes (Q22242276) (← links)
- Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? (Q24597424) (← links)
- Role of the tumor microenvironment in mature B-cell lymphoid malignancies (Q26748775) (← links)
- What lessons can be learned from γδ T cell-based cancer immunotherapy trials? (Q26849323) (← links)
- Transformed follicular non-Hodgkin lymphoma (Q26851974) (← links)
- Functional genomics lead to new therapies in follicular lymphoma (Q26852415) (← links)
- The genetic landscape of diffuse large B-cell lymphoma (Q26866537) (← links)
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review (Q27304386) (← links)
- Lymphoma: immune evasion strategies (Q28080705) (← links)
- Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? (Q33622342) (← links)
- HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? (Q33632104) (← links)
- Immune checkpoint blockade for hematologic malignancies: a review (Q33645590) (← links)
- In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). (Q33701036) (← links)
- Genetics of follicular lymphoma transformation (Q33910446) (← links)
- Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model (Q34028436) (← links)
- Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. (Q34353717) (← links)
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma (Q34366539) (← links)
- Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. (Q34388117) (← links)
- MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples (Q34636963) (← links)
- IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells (Q34651540) (← links)
- Augmenting antitumor immune responses with epigenetic modifying agents (Q35048054) (← links)
- Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis (Q35419876) (← links)
- Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes (Q35559086) (← links)
- Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines (Q35850206) (← links)
- Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. (Q35890616) (← links)
- Genetic lesions in diffuse large B-cell lymphomas (Q35974341) (← links)
- Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. (Q36003528) (← links)
- Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma (Q36051184) (← links)
- Several immune escape patterns in non-Hodgkin's lymphomas. (Q36060357) (← links)
- Microenvironment abnormalities and lymphomagenesis: Immunological aspects. (Q36118020) (← links)
- The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification (Q36280547) (← links)
- Cancer immunotherapy: Strategies for personalization and combinatorial approaches (Q36387028) (← links)
- Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease (Q36876967) (← links)
- Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies (Q37058110) (← links)
- Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission (Q37086251) (← links)
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia (Q37098861) (← links)
- TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses (Q37116255) (← links)
- Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma (Q37132882) (← links)
- Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation (Q37168346) (← links)
- Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. (Q37187384) (← links)
- Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. (Q37222108) (← links)
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome (Q37246532) (← links)
- Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine (Q37420192) (← links)
- Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma (Q37453629) (← links)
- Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model (Q37462631) (← links)
- Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. (Q37587362) (← links)
- Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma (Q37636972) (← links)
- Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors (Q37696308) (← links)
- Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses (Q37708919) (← links)
- Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions (Q38022591) (← links)